Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
EBIT MarginEBITDA MarginEBT MarginFCF MarginNet MarginOperating MarginReturn on Sales

Cogent Biosciences (COGT) Invested Capital (2017 - 2021)

Cogent Biosciences has reported Invested Capital over the past 5 years, most recently at $197.2 million for Q3 2021.

  • Quarterly results put Invested Capital at $197.2 million for Q3 2021, up 989.5% from a year ago — trailing twelve months through Sep 2021 was $197.2 million (up 989.5% YoY), and the annual figure for FY2020 was $234.7 million, up 638.83%.
  • Invested Capital for Q3 2021 was $197.2 million at Cogent Biosciences, down from $212.8 million in the prior quarter.
  • Over the last five years, Invested Capital for COGT hit a ceiling of $234.7 million in Q4 2020 and a floor of -$61.3 million in Q1 2018.
  • Median Invested Capital over the past 5 years was $44.5 million (2019), compared with a mean of $71.1 million.
  • Biggest five-year swings in Invested Capital: crashed 177.47% in 2020 and later skyrocketed 1005.99% in 2021.
  • Cogent Biosciences' Invested Capital stood at -$48.8 million in 2017, then soared by 223.31% to $60.2 million in 2018, then crashed by 47.27% to $31.8 million in 2019, then surged by 638.83% to $234.7 million in 2020, then decreased by 15.95% to $197.2 million in 2021.
  • The last three reported values for Invested Capital were $197.2 million (Q3 2021), $212.8 million (Q2 2021), and $226.8 million (Q1 2021) per Business Quant data.